Disease · MONDO_0005391
Comparisons in its trials37
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 37
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| De-novo Patients vs Pre-treated Patients: serious adverse events | 0 of 452 | 2 of 97 | 549 | NCT00721279 | Trial comparisons |
| Gabapentin Enacarbil vs Placebo: deaths from any cause | 0 of 189 | 0 of 186 | 375 | NCT03053427 | Trial comparisons |
| Gabapentin Enacarbil vs Placebo: serious adverse events | 3 of 189 | 0 of 186 | 375 | NCT03053427 | Trial comparisons |
| Pramipexole vs Placebo: serious adverse events | 8 of 166 | 3 of 163 | 329 | NCT00472199 | Trial comparisons |
| Pramipexole vs Placebo: serious adverse events | 3 of 202 | 0 of 103 | 305 | NCT00654498 | Trial comparisons |
| Pramipexole vs Placebo: Diagnosis of Classified Augmentation According to Independent Expert Panel | 18 of 152 | 14 of 149 | 301 | NCT00472199 | Trial comparisons |
| Pramipexole vs Placebo: Worsening of RLS Symptoms (by at Least 4 Points in the IRLS Total Score Compared to Baseline) After Treatment Discontinuation | 14 of 135 | 2 of 133 | 268 | NCT00472199 | Trial comparisons |
| GEn 1200 mg vs Placebo: serious adverse events | 2 of 127 | 0 of 132 | 259 | NCT00748098 | Trial comparisons |
| GEn 1200 mg vs Placebo: Number of Participants Who Were Defined as Clinical Global Impression of Illness (CGI-I) Scale Responders at Week 4/10 Using LOCF | 91 of 123 | 46 of 127 | 250 | NCT00748098 | Trial comparisons |
| GEn 1200 mg vs Placebo: Number of PLMAI Responders at Week 4/10 Using LOCF | 64 of 121 | 44 of 123 | 244 | NCT00748098 | Trial comparisons |
| GEn 1200 mg vs Placebo: Number of Participants With no Self-reported Awakenings (SPSD) Due to RLS at Week 4/10 Using LOCF | 87 of 115 | 68 of 125 | 240 | NCT00748098 | Trial comparisons |
| GEn (XP13512/GSK1838262) 600 mg vs Placebo: Number of Participants Classsified as Responders on the Investigator-rated CGI-I Scale at Week 12 Using LOCF | 83 of 114 | 43 of 96 | 210 | NCT00365352 | Trial comparisons |
| Injectafer vs Normal Saline: deaths from any cause | 1 of 107 | 0 of 101 | 208 | NCT02397057 | Trial comparisons |
| Injectafer vs Normal Saline: serious adverse events | 6 of 107 | 4 of 101 | 208 | NCT02397057 | Trial comparisons |
| GEn (XP13512/GSK1838262) 1200 mg vs Placebo: Number of Participants With a Score of Much Improved or Very Much Improved on the Investigator-rated CGI-I Scale (Response) at (Week 12) Using LOCF | 86 of 111 | 43 of 96 | 207 | NCT00365352 | Trial comparisons |
| Injectafer vs Normal Saline: Proportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression (CGI) Performed by Investigator (CGI-I) | 38 of 87 | 25 of 70 | 157 | NCT02397057 | Trial comparisons |
| Rotigotine vs Placebo: serious adverse events | 2 of 101 | 0 of 49 | 150 | NCT01569464 | Trial comparisons |
| Treatment A (Test: PR2.1.1) vs Treatment B (Reference: PR1.0): serious adverse events | 0 of 51 | 0 of 51 | 102 | NCT00881894 | Trial comparisons |
| Rotigotine PR2.2.1 vs Rotigotine PR2.1.1: serious adverse events | 0 of 49 | 0 of 49 | 98 | NCT01059903 | Trial comparisons |
| Oral Iron vs IV Iron: Number of Participants With Adverse Events Judged Related or Possibly Related to Treatment. | 22 of 46 | 11 of 47 | 93 | NCT02499354 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005391/comparisons